PriceTargets.com logo

OTCMKTS:MMEDF - Mind Medicine (MindMed) Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $2.00
  • Forecasted Upside: -41.86 %
  • Number of Analysts: 1
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 1 Buy Ratings
  • 0 Strong Buy Ratings
$3.44 As of 02/26/2021 01:00 AM ET
▼ -0.34 (-8.99%)
1 month | 3 months | 12 months
Get New Mind Medicine (MindMed) Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for MMEDF and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for MMEDF

i We calculate consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). Our consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. Our consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
$2.00
▼ -41.86% Downside Potential
This price target is based on 1 analysts offering 12 month price targets for Mind Medicine (MindMed) in the last 3 months. The average price target is $2.00, with a high forecast of $2.00 and a low forecast of $2.00. The average price target represents a -41.86% upside from the last price of $3.44.
Buy
The current consensus among 1 contributing investment analysts is to buy stock in Mind Medicine (MindMed).

Past Monthly Recommendations

Move your mouse over past months for details

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
9/6/2019
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
12/5/2019
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
3/4/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
6/2/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
8/31/2020
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
11/29/2020
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
1/28/2021
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
2/27/2021

Latest Recommendations

  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings

DateBrokerageActionRatingPrice TargetDetails
11/2/2020Canaccord GenuityBoost Price TargetBuy$1.75 ➝ $2.00
i
9/15/2020Canaccord GenuityInitiated CoverageBuy
i
(Data available from 2/28/2016 forward)
Mind Medicine (MindMed) logo
Mind Medicine (MindMed) Inc., a psychedelic medicine biotech company, discovers, develops, and deploys psychedelic inspired medicines and therapies to address addiction and mental illness. The company is assembling a compelling drug development pipeline of innovative treatments based on psychedelic substances, including Psilocybin, LSD, MDMA, DMT, and an Ibogaine derivative, 18-MC. The company is headquartered in New York, New York.
Read More

Today's Range

Now: $3.44
$3.15
$3.54

50 Day Range

MA: $3.44
$2.82
$4.19

52 Week Range

Now: $3.44
$0.08
$5.07

Volume

3,027,397 shs

Average Volume

4,169,553 shs

Market Capitalization

N/A

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Frequently Asked Questions

What sell-side analysts currently cover shares of Mind Medicine (MindMed)?

The following equities research analysts have issued stock ratings on Mind Medicine (MindMed) in the last twelve months: Canaccord Genuity.
View the latest analyst ratings for MMEDF.

What is the current price target for Mind Medicine (MindMed)?

1 Wall Street analysts have set twelve-month price targets for Mind Medicine (MindMed) in the last year. Their average twelve-month price target is $2.00, suggesting a possible downside of 41.9%. Canaccord Genuity has the highest price target set, predicting MMEDF will reach $2.00 in the next twelve months. Canaccord Genuity has the lowest price target set, forecasting a price of $2.00 for Mind Medicine (MindMed) in the next year.
View the latest price targets for MMEDF.

What is the current consensus analyst rating for Mind Medicine (MindMed)?

Mind Medicine (MindMed) currently has 1 buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe MMEDF will outperform the market and that investors should add to their positions of Mind Medicine (MindMed).
View the latest ratings for MMEDF.

What other companies compete with Mind Medicine (MindMed)?

Other companies that are similar to Mind Medicine (MindMed) include (CHV), (DDXS), (PREV), (TNGN), 138267 (COM.TO), 17031, 4basebio UK Societas, Abattis Bioceuticals, Abzena plc (ABZA.L), Acrux, Actinogen Medical, AdAlta, ADiTx Therapeutics, Admedus and Algernon Pharmaceuticals.